Sunpeaks Ventures, Inc, along with its wholly owned subsidiary Healthcare Distribution Specialists, LLC, is value added distributor of over the counter multivitamins and specialty drugs in the United States. Sunpeaks serves the specialty drug market segment estimated at $45 billion. The company’s key acquisition Healthcare Distribution Specialists (HDS) functions at present as a just-in-time supplier for hospitals for specialty products that are usually hard-to-find because of the production shortages from the drug manufacturers.
In 2011, there were more than 200 drug shortages in the United States, and according to the estimates of FDA, the shortages are only expected to worse with an increasing number of pharma manufacturers going generic. Apart from pharmaceuticals, HDS is also a national distributor for over the counter (OTC) health supplements. Sunpeaks Ventures, Inc is presently evaluating a number of OTC products that would help make the company a major OTC distributor in the growing health supplement market. The company aims to become the industry leader in the distribution of OTC vitamin products and just-in-time pharmaceuticals.
Expertise in Drug Procurement
Sunpeaks Ventures, Inc has core strengths in drug sourcing and procurement. Its team of experts is capable of supplying nearly every type of pharmaceutical in both large and small quantities. They also specialize in procurement and delivery of specialty and hard-to-find drugs.
The company can source generic, branded and over-the-counter products in all dosage forms and therapeutic classes. Expiration date and lot requirements are followed rigidly. Sunpeaks has a proven track record of shipping within the United States and abroad to clinical sites, depots, sponsor companies, and clinical packagers across various locations.
Specialty Programs and Products
Sunpeaks subsidiary Healthcare Distribution Specialists has developed specialty drug programs designed to cater to a wide spectrum of clients. Each program is run efficiently by a dedicated account team that is in touch with the pulse of the market, and the currently prevailing trends and challenges faced by the client. HDS has the resources to provide personalized service, speedy delivery, sourcing of hard-to-find products, highly competitive pricing and everyday overall value to its clients.
The company sources its portfolio of drugs and health products through a wide array of licensed providers across the United States. The range includes a full line of products, including surgical, orthopaedic, vaccines, women’s health, oncology, and plasma derivatives. The company also deals in other products including generics, antibiotics, oncologics, respiratory products, vaccines, haemolytic factors, immune globulins, and sterile injectibles.
Mackie A. Barch is the CEO of Sunpeaks Ventures and a co-founder of its wholly owned subsidiary Healthcare Distribution Specialists, LLC (HDS). Prior to the launch of HDS, Barch had co-founded Global Nutritional Research, which produces OTC products for particular disease states based on an interaction of Rx and OTC. He entered the secondary wholesale pharmaceutical industry in 2007, making a career shift from the financial services industry. Barch has participated in several equity offerings, which include IPO, 144a and Secondary Offerings.
Matthew Swift is the Executive VP of Sales at Sunpeaks Ventures, and a co-founder of HDS. Swift has been a crucial player in growth and development of two leading drug wholesalers, Premium Rx National (PRN) and Global Pharmaceutical Sourcing (GPS). The top management at Sunpeaks also includes Justin Barch, who is the Executive VP of Health Supplements Division and a co-founder of HDS. Barch is the founder and CEO of Global Nutritional Research (GNR), a company that produces OTC products. Prior to founding GNR, Barch was an Investment Advisor at Morgan Stanley Smith Barney in Bethesda, where he built investment portfolios for key families with high net worth. Before that he was an investment advisor for five years at Johnston, Lemon & Co., a private investment bank.